157 related articles for article (PubMed ID: 2777038)
1. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus.
Fennerty MB; Sampliner RE; Way D; Riddell R; Steinbronn K; Garewal HS
Gastroenterology; 1989 Oct; 97(4):815-20. PubMed ID: 2777038
[TBL] [Abstract][Full Text] [Related]
2. Correlation of ultrastructural aberrations with dysplasia and flow cytometric abnormalities in Barrett's epithelium.
Levine DS; Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1989 Feb; 96(2 Pt 1):355-67. PubMed ID: 2910757
[TBL] [Abstract][Full Text] [Related]
3. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort.
Reid BJ; Blount PL; Rubin CE; Levine DS; Haggitt RC; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1212-9. PubMed ID: 1551528
[TBL] [Abstract][Full Text] [Related]
4. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma.
Reid BJ; Haggitt RC; Rubin CE; Rabinovitch PS
Gastroenterology; 1987 Jul; 93(1):1-11. PubMed ID: 3582897
[TBL] [Abstract][Full Text] [Related]
5. Methylene blue staining of dysplastic and nondysplastic Barrett's esophagus: an in vivo and ex vivo study.
Canto MI; Setrakian S; Willis JE; Chak A; Petras RE; Sivak MV
Endoscopy; 2001 May; 33(5):391-400. PubMed ID: 11396755
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry.
Ramel S; Reid BJ; Sanchez CA; Blount PL; Levine DS; Neshat K; Haggitt RC; Dean PJ; Thor K; Rabinovitch PS
Gastroenterology; 1992 Apr; 102(4 Pt 1):1220-8. PubMed ID: 1551529
[TBL] [Abstract][Full Text] [Related]
7. [Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases].
Robaszkiewicz M; Hardy E; Volant A; Nousbaum JB; Cauvin JM; Calament G; Robert FX; Saleun JP; Gouerou H
Gastroenterol Clin Biol; 1991; 15(10):703-10. PubMed ID: 1816011
[TBL] [Abstract][Full Text] [Related]
8. Barrett's esophagus. Correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk.
Haggitt RC; Reid BJ; Rabinovitch PS; Rubin CE
Am J Pathol; 1988 Apr; 131(1):53-61. PubMed ID: 3354644
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 expression in esophageal epithelium before and after photodynamic therapy for Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma.
Yachimski P; Mino-Kenudson M; Sherwood ME; Puricelli WP; Nishioka NS; Lauwers GY
Virchows Arch; 2011 Dec; 459(6):581-6. PubMed ID: 22081106
[TBL] [Abstract][Full Text] [Related]
10. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus.
Hong MK; Laskin WB; Herman BE; Johnston MH; Vargo JJ; Steinberg SM; Allegra CJ; Johnston PG
Cancer; 1995 Jan; 75(2):423-9. PubMed ID: 7812911
[TBL] [Abstract][Full Text] [Related]
11. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group.
Menke-Pluymers MB; Mulder AH; Hop WC; van Blankenstein M; Tilanus HW
Gut; 1994 Oct; 35(10):1348-51. PubMed ID: 7959183
[TBL] [Abstract][Full Text] [Related]
12. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus.
Levine DS; Haggitt RC; Blount PL; Rabinovitch PS; Rusch VW; Reid BJ
Gastroenterology; 1993 Jul; 105(1):40-50. PubMed ID: 8514061
[TBL] [Abstract][Full Text] [Related]
13. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
14. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.
Reid BJ; Levine DS; Longton G; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2000 Jul; 95(7):1669-76. PubMed ID: 10925966
[TBL] [Abstract][Full Text] [Related]
15. Barrett's esophagus: development of dysplasia and adenocarcinoma.
Hameeteman W; Tytgat GN; Houthoff HJ; van den Tweel JG
Gastroenterology; 1989 May; 96(5 Pt 1):1249-56. PubMed ID: 2703113
[TBL] [Abstract][Full Text] [Related]
16. Detection of high-grade dysplasia in Barrett's esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence.
Brand S; Wang TD; Schomacker KT; Poneros JM; Lauwers GY; Compton CC; Pedrosa MC; Nishioka NS
Gastrointest Endosc; 2002 Oct; 56(4):479-87. PubMed ID: 12297761
[TBL] [Abstract][Full Text] [Related]
17. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.
Hamilton SR; Smith RR
Am J Clin Pathol; 1987 Mar; 87(3):301-12. PubMed ID: 3825997
[TBL] [Abstract][Full Text] [Related]
18. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression.
Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS
Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.
Wani S; Rubenstein JH; Vieth M; Bergman J
Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561
[TBL] [Abstract][Full Text] [Related]
20. DNA ploidy status and proliferative activity as markers of malignant potential in Barrett's esophagus: flow cytometric study using routinely paraffin-embedded tissue.
Giménez A; Minguela A; de Haro LM; Parrilla P; Bermejo J; Pérez D; García AM; Ortiz MA; Molina J; Alvarez R
World J Surg; 2000 Jan; 24(1):72-7. PubMed ID: 10594207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
